Kornimate/medical-research-clean huggingface dataset:
the effects of erythropoietin on clinical disability and brain pathology in patients with progressive multiple sclerosis

Conditions: Multiple Sclerosis (Primary or Secondary Progressive Phase).

Summary: in a double-blind, placebo-controlled, parallel group trial, recombinant human erythropoietin (rhepo) (48000 iu) treatment or placebo will be administered weekly i.v. for 24 weeks: weekly for 12 weeks and bi-weekly for 12 weeks. methylprednisolone (mp) 1 g i.v. will be administered before the first and second epo/placebo administration. the 24-week treatment period will be followed by a 24-week observation period.

patients with primary progressive ms or secondary progressive ms without relapses during the last 1 year will be suitable for the trial. in all 56 patients will be enrolled into the study. the primary outcome measure is the change from baseline to 24 weeks in a composite of maximum gait distance, 9-hole peg test, trail making b comparing the placebo-treatment group with the epo-treatment group.

Eligibility criteria:
inclusion criteria: * age between 19 and 60 years * primary progressive ms or secondary progressive ms without relapses during the last one year * duration of the disease of at least 2 years clinical disability progression should have been observed in the 2 years prior to screening as per clinical judgment of the investigator. in addition, progression must be documented by an increase in the edss score of at least 0.5 points at any time during the 2 years prior to screening; or progression of 1 point in the pyramidal, cerebellar, brain stem , visual or sensory functional system during the last 2 years. should documented edss scores not be available, a written summary of the clinical evidence of disability progression in the previous 2 years must be submitted (for example walking distance or hand function). * edss (expanded disability status scale) 4.0-6.5 * mri fulfilling the barkhof criteria for ms * written informed consent exclusion criteria: * pregnancy or period of breastfeeding or missing adequate contraceptive protection * treatment with steroids in the last 30 days * treatment with interferons, glatiramer acetate or ivig in the last1 month prior to enrolment * treatment with azathioprin, mitoxantrone or any other immuno-suppressive in the 6 months prior to enrolment * cardiac insufficiency (nyha iii/iv), cardiomyopathy, significant cardiac dysrhythmia requiring treatment, instable or advanced ischemic heart disease (ccs iii or iv), malignant hypertension (systolic \> 180, diastolic \> 110) * history of any haematological disorder * history of renal insufficiency * any medical psychiatric or other circumstances which impede or restrict the subjects participation in the study in the manner intended * contraindication for contrast enhanced mri (e.g. pace maker, aortic clip or any metal implant)

Keywords: progressive multiple sclerosis
exercise and soft tissue sarcoma

Conditions: Soft Tissue Sarcoma

Summary: the purpose of this study is to evaluate the effect of a neoadjuvant (i.e. pre-treatment) exercise regimen on extremity function and postoperative wound healing. the study group will include patients with a primary diagnosis of soft tissue sarcoma undergoing treatment with neoadjuvant radiation therapy and surgical resection. patients with upper or lower extremity sarcomas will be considered for enrollment.


Eligibility criteria:
inclusion criteria: 1. males and females within the ages of 18-85 2. diagnosis of soft tissue sarcoma that has been histologically confirmed by an approved reference pathologist 3. sarcoma of the upper or lower extremity location 4. treatment plan that includes neo-adjuvant radiation therapy followed by surgical resection 5. expected primary wound closure performed at the time at surgery 6. any disease stage 7. any tumor grade 8. any histologic subtype 9. first or recurrent presentations 10. no vascular invasion or resection/repair/reconstruction that results in decreased perfusion of the extremity 11. no history of radiation therapy to the tumor and/or surgical area prior to the current treatment being studied 12. must be able to comply with follow up visits 13. must be able to provide own consent exclusion criteria: 1. patients under the age of 18, or over the age of 85 2. treatment plan that does not include neo-adjuvant radiation and surgical excision 3. sarcoma location other than the upper or lower extremity 4. history of radiation therapy to the tumor and/or surgical area prior to the current treatment being studied 5. high dose steroid therapy (defined as \>5mg prednisone, or equivalent, with the last 30 days) 6. active treatment with chemotherapy within the last 30 days 7. inability of the patient to provide informed consent (i.e. dementia, cognitive impairment, non-english speakers) 8. plan for post-operative radiation therapy 9. underlying severe cardiopulmonary disease 10. prior surgery, other than a biopsy, at the site of disease 11. tumors that are ulcerative or fungating through the dermis at the time of presentation 12. vascular invasion or resection/repair/reconstruction that results in decreased perfusion of the extremity 13. vascular disease resulting in clinically apparent compromise in blood flow to the treatment extremity (i.e. peripheral vascular disease with diminished pulses, venous insufficiency with clinical evidence of vascular congestion) 14. actively uncontrolled diabetes mellitus (documentation of history of diabetes with a1c\>8) 15. active deep vein thrombosis in the treatment extremity 16. inability to comply with follow up visits 17. pregnant females (women of childbearing potential must have a negative serum pregnancy test prior to enrollment)

Keywords: exercise soft tissue sarcoma sts
golimumab safety and surveillance program using the ingenix nhi database

Conditions: Rheumatoid Arthritis; Arthritis, Psoriatic; Ankylosing Spondylitis

Summary: the participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse us health plan.the objective of this study is to estimate the rate of serious infections, tuberculosis, malignancies, and other outcomes in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients treated with golimumab, anti-tumor necrosis factor (tnf) biologics, non-anti-tnf biologics, or systemic non-biological treatments.

the participants included in this study will be drawn from the ingenix normative health informatics database, a proprietary research database containing claims and enrollment data dating back to 1993 for members of a large, geographically diverse us health plan. this study will include cohorts of participants who have claims consistent with a diagnosis of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis and who initiate golimumab, anti-tnf biologics, non-anti-tnf biologics, or systemic non-biological treatments. participants will be identified by claims bearing codes for dispensed drugs, procedures or diagnoses and followed after the launch of golimumab for up to 8 years. a sample of enrolled health plan members without claims evidence of diagnosis or treatment of rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis will also be selected. the claims database will be used to estimate the incidence of the primary outcomes of serious infections, tuberculosis (tb) and non-tb mycobacterial infections, malignancies such as lymphoma, and other selected outcomes. no study agents will be administered in this study. all participants will receive standard-of-care treatment as prescribed by their physician

Eligibility criteria:
inclusion criteria: * complete medical coverage and pharmacy benefits * six months of continuous enrollment prior to the date of cohort entry exclusion criteria: * participants will be excluded if they do not have information on age, gender or enrollment

Keywords: rheumatoid arthritis psoriatic arthritis ankylosing spondylitis golimumab anti-tnf biologics non-anti-tnf biologics non-biological treatments
external oblique intercostal plane block for patients undergoing upper abdominal surgeries

Conditions: Post Operative Pain

Summary: ithe study will evaluate the analgesic efficacy of external oblique intercostal block for patients undergoing upper abdominal surgeries

patients will be randomly divided into two equal groups using spss. group a: will receive us-guided external oblique intercostal block after induction group b: will receive postoperative morphine on patient request. study design: prospective controlled randomized study.

Eligibility criteria:
inclusion criteria: * selected patients will be more than 21 years old with asa physical status i \& ii scheduled for upper abdominal surgeries exclusion criteria: uncooperative patients. * patients who have allergy to any of the used drugs. * patients who are on opioids. * known abuse of alcohol or medication. * local infection at the site of injection or systemic infection. * pregnancy * patients with coagulation disorders or on anticoagulation therapy
efficacies of tetracycline-levofloxacin, standard bismuth, amoxicillin-levofloxacin quadruple therapy for h.p

Conditions: Helicobacter Pylori Eradication

Summary: 1. compare the efficacy of "tetracycline combined with levofloxacin quadruple therapy", "standard tincture quadruple therapy" and "amoxicillin combined with levofloxacin quadruple therapy" on the second line of helicobacter pylori sterilization. 2. to investigate the drug resistance of helicobacter pylori and the host genotypes of cyp2c19 and il-1b-511 on the sterilizing effect of three second-line helicobacter pylori.

the "standard tincture quadruple therapy" and the "proton pump inhibitor combined with fluoroquinolone and amoxicillin triple therapy" recommended by the 5th mazdock-florence consensus conference on the second line of helicobacter pylori treatment the sterilization rate is not ideal (less than 80%). recently, we have developed a "tetracycline combined with levofloxacin quadruple therapy" for first-line treatment failure of h. pylori infection, with a relatively high sterilization rate (\> 95%). a randomized controlled trial confirmed that the elimination rate of "tetracycline combined with levofloxacin quadruple therapy" was better than "proton pump inhibitor combined with fluoroquinolone" after "standard triple therapy" and "non-tank tetratherapy" sterilization failure. triple therapy with amoxicillin.

Eligibility criteria:
inclusion criteria: 1. at least 20 years old 2. subject was failure for the first line therapy of helicobacter pylori exclusion criteria: 1. those who are allergic to the drugs used in this study 2. those who have had a stomach surgery 3. those who have antibiotics within four weeks of treatment 4. those who have severe cirrhosis, uremia or malignancy 5. those who are a pregnant woman or a woman who breastfeeds
a study of ruxolitinib in combination with capecitabine in subjects with advanced or metastatic her2-negative breast cancer

Conditions: Breast Cancer

Summary: this was a randomized, double-blind, placebo-controlled phase 2 clinical trial comparing the overall survival of women with advanced or metastatic her2-negative breast cancer who received treatment with capecitabine in combination with ruxolitinib versus those who received treatment with capecitabine alone.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed her2-negative adenocarcinoma of the breast * locally advanced (stage 3b) or metastatic (stage 4) disease * eastern cooperative oncology group (ecog) performance status 0 to 2 * received up to 2 prior chemotherapy regimens (not including neoadjuvant/adjuvant therapy) for advanced or metastatic disease * participants with hormone-receptor positive tumors must have failed available lines of hormonal therapy unless hormone therapy was not tolerated or not clinically appropriate * ≥ 2 weeks elapsed from the completion of previous treatment regimen and must have recovered or be at a new stable baseline from any related toxicities * radiographically measurable or evaluable disease * an mgps of 1 or 2 as defined below: * criteria: 1. modified glasgow prognostic score (mgps) of 1: crp \> 10 mg/l and albumin ≥ 35 g/l 2. mgps of 2: c-reactive protein (crp) \> 10 mg/l and albumin \< 35 g/l exclusion criteria: * received prior treatment with capecitabine or fluoropyrimidine for advanced or metastatic disease * received more than 2 prior regimens for advanced or metastatic disease (not including hormonal therapy in the metastatic setting or neoadjuvant or adjuvant therapies) * unknown hormone-receptor status * ongoing radiation therapy or radiation therapy administered within 2 weeks of enrollment * concurrent anticancer therapy * inadequate renal, hepatic or bone marrow function * another current or previous malignancy within 2 years of study entry unless approved by the sponsor

Keywords: breast cancer
feeding during ibuprofen or indomethacin treatment of preterm infants

Conditions: Patent Ductus Arteriosus

Summary: we hypothesize that feeding preterm infants while they receive indomethacin or ibuprofen therapy for treatment of a patent ductus arteriosus will decrease the incidence of feeding intolerance and shorten the time period that infants need to tolerate full enteral nutrition. we also hypothesize that this intervention will minimize the alterations in intestinal permeability that occur with these drugs and will improve the infants' hemodynamic response to enteral nutrition

this study is a randomized controlled multi-center clinical trial to determine whether very low birth weight infants should receive feedings during indomethacin or ibuprofen treatment of a patent ductus arteriosus (pda). many neonatologists withhold feeds from premature infants receiving indomethacin or ibuprofen therapy for a pda because of concerns that these drugs alter intestinal blood flow and permeability. however, there are no established studies which show that feeding during these medical treatments leads to bowel injury. at the same time, studies suggest that withholding feedings from premature infants may lead to intestinal atrophy and injury, leading to increased difficulty with feedings when they are initiated or re-started. thus, this multi-center study evaluates whether feeding infants during indomethacin or ibuprofen therapy improves feeding tolerance by measuring the number of episodes of feeding intolerance and the number of days required to attain full feedings. in addition, this study will employ techniques to measure gastrointestinal permeability and mesenteric blood flow in patients who receive and don't receive feedings for their pda treatment.

Eligibility criteria:
inclusion criteria: * infants between 401-1,250 g birth weight who * are receiving or are scheduled to begin enteral feedings and * are about to receive pharmacologic treatment (either indomethacin or ibuprofen) to close their pda. exclusion criteria: * serious congenital malformations * chromosomal anomalies * congenital or acquired gastrointestinal anomalies * prior episode of necrotizing enterocolitis * use of inotropic support for hypotension * renal anomalies or disease * are receiving \> 80 ml/kg/d of enteral feeding

Keywords: indomethacin ibuprofen preterm infant
chiropractic for back and neck pain in an emergency department setting

Conditions: Back Pain; Neck Pain; Anxiety

Summary: this study aims to examine the efficacy of an integrative approach utilizing chiropractic as an add-on therapy for the treatment back and neck pain in an emergency department setting chiropractic is well established as an effective treatment for back pain. the investigators cumulative experience in asaf harofeh medical center has shown chiropractic to be an effective therapy for simple back and neck pain in an emergency room (er) setting. this study will examine weather chiropractic can decrease pain, increase range of motion and decrease anxiety in patients admitted to the emergency room with simple back and neck pain without neurological findings. chiropractic will be performed as an add on therapy on top of analgesic therapy.


Eligibility criteria:
inclusion criteria: * adult male and females age 18-60 with acute or sub acute/chronic simple back or neck pain * agreed to a physical examination and by an orthopedic physician and x-ray diagnosis of simple back pain with levels of 4 \< nrs at least * agreed and able to fill pain, anxiety and satisfactory questioners * agreed and able to sign informed consent exclusion criteria: * fracture, sprain or neurological deficit during physical examination * pain scale of nrs \< 4 * active pregnancy * active inflammatory arthritis * history of cva * open wounds * acute malignancy with life expectancy of less than 5 years * experience with acupuncture treatments * history of drug addiction * history of osteoporosis * declined or unable to sign informed consent * soldiers in active military service * received a chiropractic treatment in the past

Keywords: back pain neck pain anxiety range of motion
growth hormones and cells in human milk depending on gestational age

Conditions: Lactation

Summary: human breast milk contains growth factors including neurotrophins and cells with neuroprotective potential. concerning growth factors milk of preterms differs significantly from term milk. the aim of this study is to give a profile of human milk concerning non-nutritive factors depending on gestational age and lactation phase.

neurotrophins (epidermal growth factor (egf), vascular endothelial growth factor (vegf), nerve growth factor (ngf), brain derived neurotrophic factor (bdnf)) as well as amount of cells, especially positive for sex-determining transformer protein (tra)-1-81 and stage-specific embryonic antigen (ssea)-4, are planned to be quantified in human breast milk of extremely preterm newborns as well as term newborns at different stages of lactation.

Eligibility criteria:
inclusion criteria: * the newborn infant is being fed with own mothers milk exclusion criteria: * low amount of breast milk

Keywords: neurotrophins stem cells prematurity
acupressure wristbands for glp-1ra related nausea

Conditions: Nausea

Summary: nausea is a common side effect of glp-1ra medications used for treatment of type 2 diabetes mellitus and obesity. current recommendations for nausea relief include the use of dietary changes and prescription anti-emetics. acupressure wristbands sea-band are fda cleared for nausea relief in other indications such as motion sickness, morning sickness in pregnancy, post-operative nausea, chemotherapy associated nausea. we hypothesized that acupressure wristbands could alleviate nausea in persons taking glp-1ra.

nausea is the most commonly reported side effect of the class of drugs collectively known as glucagon like peptide-1 receptor agonists (glp-1ra). glp-1ras are fda approved to treat type 2 diabetes mellitus (t2dm) and obesity. sea-band is an fda-cleared set of drug-free elastic wristbands used for nausea relief in several indications including motion sickness, morning sickness in pregnancy, post-operative nausea, chemotherapy associated nausea in persons ages 3 years old and up. the elastic wristbands have a plastic skin facing knob that apples pressure to an acupressure point called pericardium 6 (p6) located below the crease of the wrist. we hypothesize that sea-band can alleviate nausea in persons taking glp-1ra. participants on glp-1ra medication with nausea were offered a set of acupressure wristbands, and followed for four weeks. weekly touch points assessed the response to nausea relief of the bands. eligibility for the study included adults taking glp-1ra experiencing nausea.

Eligibility criteria:
inclusion criteria: * adults taking glp-1ra with nausea exclusion criteria: * adults on glp-1ra without nausea * uncontrolled gerd * hx of gastroparesis * other nausea related conditions such as vertigo * history of chronic use of antiemetic medication for other reasons

Keywords: nausea relief acupressure wristbands glp-1 medication obesity
psychological morbidity and facial volume in hiv lipodystrophy: quantification of treatment outcome

Conditions: HIV-Associated Lipodystrophy Syndrome

Summary: the hypotheses of this study were that: 1. hiv lipodystrophy is associated with psychological morbidity relating to body image, anxiety and depression. 2. treatment of hiv lipodystrophy using autologous fat transfer, polylactic acid or bio-alcamid, is associated with an improvement in psychological morbidity and anatomical volume of treated areas. 3. the di3d system is a valid and reproducible method of recording and measuring facial 3-d volume.

as above

Eligibility criteria:
inclusion criteria: * hiv facial lipoatrophy * concurrent antiretrovirals exclusion criteria: * known psychological disorder * skin allergies * significant medical problems precluding anaesthesia
comparing mentalization-based treatment and a dialectical behavior therapy-inspired treatment on the utilization of services and the dropout rate in a clinical adult population with a cluster b personality disorder

Conditions: Cluster B Personality Disorder (Diagnosis); Borderline Personality Disorder

Summary: cluster b personality disorders (borderline, narcissistic, antisocial and/or histrionic) are an important clinical consideration because of their high prevalence and associated morbidity. although many studies examine borderline personality disorder, few of them explore cluster b personality disorders as a whole. in clinical practice, personality disorders are frequently comorbid. patients who receive services in specialized clinics for these disorders often have a complex diagnosis that include many cluster b personality disorders. therefore, our study globally examines patients with cluster b personality disorders even though borderline personality disorder is empirically the most studied psychopathology. previous data suggests that borderline personality disorder has a prevalence of 2% in the general population, of 25% in the clinical psychiatric population and of 15% in all visits to the emergency room. furthermore, it is associated with social costs estimated from 15,000$ to 50,000$ usd per patient per year. in quebec, this psychopathology is associated with an increased mortality rate compared to the general population, totaling a loss of nine years for women and 13 years for men of life expectancy. other studies suggest that borderline personality disorder is often comorbid with other personality disorders, including those in cluster b. the population with comorbid personality disorders have a worse prognosis and a lower chance of reaching symptomatic remission, which is the reason why it is crucial to better understand and study patients with cluster b personality disorders. the study compares the effectiveness of two psychotherapies for borderline personality disorder, mentalization-based therapy and a modified version of linehan's dialectical behavior therapy, in a retrospective naturalistic study of patients with at least one cluster b personality disorder who have undergone either treatment. the scarcity of data on cluster b personality disorders and on the comparison between mbt and dbt further highlights the necessity of a naturalistic study like ours to examine both aspects and bring research closer to the clinical setting. based on clinical observations, the investigators believe that there will be no statistically significant difference between either treatment.


Eligibility criteria:
inclusion criteria: * meet the general criteria for a personality disorder * be diagnosed with at least one cluster b personality disorder * be admitted to the service of personality and relational disorders and referred to mentalization-based treatment or a treatment inspired from dialectical behavior therapy exclusion criteria: * none

Keywords: cluster b personality disorder mentalization-based treatment dialectical behavior therapy borderline personality disorder service utilization dropout rate naturalistic study